CND Life Sciences

CND Life Sciences congratulates Michael J. Fox for receiving the Presidential Medal of Freedom for his dedication to speeding up a cure for #ParkinsonsDisease. We're proud to be part of the community of advocates, scientists, and innovators advancing the understanding and treatment of neurodegenerative diseases like #Parkinsons. Read the news release here: https://lnkd.in/gKbyympk The Michael J. Fox Foundation for Parkinson's Research CND Life Sciences Rick Morello Todd Levine Padma R. Mahant, MD #Advocacy #MichaelJFox #MedalOfFreedom #ParkinsonsResearch 

NeurologyLive covers recent findings showing the clinical utility of CND Life Sciences’ Syn-One Test® –and how clinicians use it to inform patient referrals to physical, occupational, and speech therapy.    “Our study demonstrated that synuclein skin biopsy influenced the diagnosis or management in 78% of cases, underscoring the potential of the Syn-One Test to change the paradigm in diagnosing these conditions, providing greater clarity, and ensuring patients receive appropriate care and treatment options," said Jonathan Isaacson, MD, who led the study at the Center of Autonomic and Peripheral Nerve Disorders at Beth Israel Deaconess Medical Center (BIDMC). https://lnkd.in/gQj8CcyS   Get the full story here - https://lnkd.in/gh-SfZgz #parkinsons #ParkinsonsDisease #ParkinsonsResearch #cndlifesciences Todd Levine Rick Morello Padma R. Mahant, MD

Wishing you and your loved ones a happy holiday season and all the best for the New Year!

The research keeps coming. CND Life Sciences announces that a retrospective chart review of 97 patients published in the December 18, 2024, issue of Frontiers in Neurology shows that the results of the Syn-One Test effected a change in the clinical care of 78% of the patients. The publication demonstrated the clinical utility of skin biopsy testing in the diagnosis and evaluation of synucleinopathies. These diseases, which include #ParkinsonsDisease, #dementiawithLewybodies, and #multiplesystematrophy, are often difficult to diagnose accurately leading to delays or errors in medical management.    “For too long, neurologists have needed a simple, accurate test to help diagnose Parkinson’s disease, dementia with Lewy bodies, and other related disorders,” said Todd Levine, MD, Chief Medical Officer of CND Life Sciences. “This study shows that by examining nerves in the skin, the Syn-One Test® fulfills that need and contributes to clinical practice and decision-making.    See the full news release https://lnkd.in/gcwJArzn   #DementiawithLewybodies #ParkinsonsResearch #Parkinsons #CNDLifeSciences #FrontiersInNeurology Rick Morello Padma R. Mahant, MD

Members from CND Life Sciences Medical and Commercial teams were excited to attend the Parkinson Study Group conference last week to hear about the latest advances in #Parkinsons research and connect with others at the Women in Neurology forum! #ParkinsonsDisease #ParkinsonsResearch #womeninneurology #neurology #CNDLifeSciences https://lnkd.in/eKD2QwR

Changes in our skin may offer important clues about #ParkinsonsDisease and how it progresses. CND Life Sciences is conducting a clinical study designed to understand #Parkinsons better using the Syn-One Test® to detect the level of phosphorylated alpha-synuclein (P-SYN) in the skin over time.    “Our hope is that if we can show that we can accurately quantify the amount of P-SYN over time, we will have an objective measure for how the disease progresses,” said Todd Levine, MD, Chief Medical Officer of CND, “and a potential way to measure the effectiveness of drugs being developed to reduce P-SYN.”    Rick Morello Padma R. Mahant, MD #parkinsonsresearch #alphasynuclein https://lnkd.in/eKD2QwR

CND Life Sciences' Synuclein-One Study, published in JAMA, Journal of the American Medical Association, has been featured in an article from Parkinson's Foundation “Top Parkinson’s Science News Articles of 2024.” The NIH-supported, blinded, multicenter study demonstrated the high positivity rate of the Syn-One Test® to detect phosphorylated #alphasynuclein in patients with clinically confirmed #synucleinopathies such as #ParkinsonsDisease and #DementiaWithLewyBodies.  We are honored to see this important research recognized.  Click here to read the article: https://lnkd.in/dfMRJmvh Visit CND Life Sciences at https://lnkd.in/eKD2QwR #Parkinsons #ParkinsonsResearch #JAMA #CNDLifeSciences  Todd Levine Rick Morello Padma R. Mahant, MD

Honored to be a part of the Parkinson Study Group Industry Forum and learn about the latest advances in Parkinson's disease and movement disorders research.

The skin test for separating Parkinson's vs. MSA. Chris Gibbons presented some data and engaged the audience a great discussion today. Check out this paper on the topic. Also his favorite movie is Monty Python, Holy Grail. Great Parkinson's Foundation panel today in Nashville.

CND Life Sciences is excited to share our insights and learn from other innovators at the 33rd Annual Meeting of the Parkinson Study Group in Nashville. Join CND's Chief Medical Officer, Todd Levine, MD at the Industry Forum on Saturday, December 7th, at 2:30 PM in Grand Hall D & E.   We look forward to seeing you there!   Rick Morello Padma R. Mahant, MD CND Life Sciences #PSG2024 #CNDLifeSciences #ParkinsonsResearch #parkinsons #parkinsonsdisease